Central nervous system primitive neuroectodermal tumor

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Central nervous system primitive neuroectodermal tumor
Synonyms	CNS PNET
Pronounce	N/A
Specialty	N/A
Symptoms	Headache, nausea, vomiting, seizures, neurological deficits
Complications	Hydrocephalus, metastasis
Onset	Typically in children and young adults
Duration	Variable
Types	Medulloblastoma, pineoblastoma, ependymoblastoma
Causes	Unknown
Risks	Genetic predisposition, radiation exposure
Diagnosis	MRI, CT scan, biopsy
Differential diagnosis	Medulloblastoma, atypical teratoid rhabdoid tumor, ependymoma
Prevention	N/A
Treatment	Surgery, radiation therapy, chemotherapy
Medication	N/A
Prognosis	Variable, depends on type and stage
Frequency	Rare
Deaths	Varies

Central nervous system primitive neuroectodermal tumor (CNS PNET) is a rare and highly aggressive cancer that primarily affects children and young adults. It is a type of neuroectodermal tumor that originates from the neural crest cells in the central nervous system.

Classification

CNS PNETs are classified as embryonal tumors, a category of neoplasms that also includes medulloblastoma and atypical teratoid rhabdoid tumor (ATRT). They are further classified based on their location in the brain, with the most common types being cerebral, pineal, and spinal.

Symptoms

The symptoms of CNS PNETs vary depending on the location of the tumor. Common symptoms include headache, nausea, vomiting, and changes in behavior or personality. In some cases, the tumor may cause seizures or neurological deficits.

Diagnosis

Diagnosis of CNS PNETs typically involves a combination of neuroimaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, and biopsy to confirm the diagnosis. Histopathology and immunohistochemistry are also used to differentiate CNS PNETs from other types of brain tumors.

Treatment

Treatment for CNS PNETs usually involves a combination of surgery, radiation therapy, and chemotherapy. The goal of treatment is to remove as much of the tumor as possible and to kill any remaining cancer cells. Despite aggressive treatment, the prognosis for CNS PNETs is generally poor, with a five-year survival rate of less than 50%.

Research

Research into CNS PNETs is ongoing, with a focus on understanding the genetic and molecular mechanisms that drive these tumors. This research may lead to the development of new treatments and improve the prognosis for individuals with this disease.

Gallery

• 
  Histology of Medulloepithelioma
• 
  Ependymoblastomatous Rosette
• 
  MRI of Central nervous system primitive neuroectodermal tumor